Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$7.1b

Bio-Rad Laboratories Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BIO ($262.8) is trading below our estimate of future cash flow value ($415.46)

Significantly Below Future Cash Flow Value: BIO is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Key metric: As BIO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIO. This is calculated by dividing BIO's market cap by their current earnings.
What is BIO's PE Ratio?
PE Ratio9.3x
EarningsUS$759.90m
Market CapUS$7.10b

Price to Earnings Ratio vs Peers

How does BIO's PE Ratio compare to its peers?

The above table shows the PE ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.5x
RGEN Repligen
131.6x29.81%US$6.4b
ICLR ICON
12.5x7.88%US$7.4b
TECH Bio-Techne
98.1x23.82%US$8.1b
QGEN Qiagen
19.7x12.41%US$8.5b
BIO Bio-Rad Laboratories
9.3x-19.90%US$7.1b

Price-To-Earnings vs Peers: BIO is good value based on its Price-To-Earnings Ratio (9.3x) compared to the peer average (65.5x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BIO's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
BIO 9.3xIndustry Avg. 34.2xNo. of Companies4PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIO is good value based on its Price-To-Earnings Ratio (9.3x) compared to the US Life Sciences industry average (32.9x).

Price to Earnings Ratio vs Fair Ratio

What is BIO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.3x
Fair PE Ratio12.6x

Price-To-Earnings vs Fair Ratio: BIO is good value based on its Price-To-Earnings Ratio (9.3x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$262.80
US$324.00
+23.29%
9.63%US$375.00US$280.00n/a5
Mar ’27US$278.44
US$324.00
+16.36%
9.63%US$375.00US$280.00n/a5
Feb ’27US$293.70
US$348.00
+18.49%
5.93%US$375.00US$325.00n/a5
Jan ’27US$302.99
US$348.00
+14.86%
5.93%US$375.00US$325.00n/a5
Dec ’26US$321.50
US$348.00
+8.24%
5.93%US$375.00US$325.00n/a5
Nov ’26US$319.55
US$348.00
+8.90%
5.93%US$375.00US$325.00n/a5
Oct ’26US$297.95
US$310.00
+4.04%
10.35%US$350.00US$265.00n/a5
Sep ’26US$297.88
US$326.50
+9.61%
14.43%US$409.00US$265.00n/a6
Aug ’26US$284.60
US$326.50
+14.72%
14.43%US$409.00US$265.00n/a6
Jul ’26US$247.99
US$315.33
+27.16%
15.09%US$387.00US$245.00n/a6
Jun ’26US$226.93
US$318.67
+40.43%
14.25%US$392.00US$260.00n/a6
May ’26US$240.43
US$353.17
+46.89%
15.96%US$409.00US$270.00n/a6
Apr ’26US$240.00
US$365.00
+52.08%
13.79%US$430.00US$285.00n/a6
Mar ’26US$265.16
US$372.83
+40.61%
12.69%US$447.00US$315.00US$278.446
Feb ’26US$360.88
US$404.33
+12.04%
13.83%US$481.00US$315.00US$293.706
Jan ’26US$328.51
US$404.33
+23.08%
13.83%US$481.00US$315.00US$302.996
Dec ’25US$340.53
US$402.33
+18.15%
13.25%US$469.00US$315.00US$321.506
Nov ’25US$368.42
US$399.00
+8.30%
14.13%US$469.00US$315.00US$319.556
Oct ’25US$337.69
US$388.50
+15.05%
12.00%US$446.00US$315.00US$297.956
Sep ’25US$337.32
US$372.67
+10.48%
10.81%US$430.00US$315.00US$297.886
Aug ’25US$341.25
US$366.40
+7.37%
13.76%US$430.00US$300.00US$284.605
Jul ’25US$263.97
US$366.40
+38.80%
13.76%US$430.00US$300.00US$247.995
Jun ’25US$286.86
US$393.80
+37.28%
12.81%US$440.00US$300.00US$226.935
May ’25US$274.06
US$419.90
+53.21%
6.18%US$441.00US$365.00US$240.436
Apr ’25US$338.98
US$435.73
+28.54%
5.57%US$480.00US$400.00US$240.006
Mar ’25US$332.30
US$435.73
+31.13%
5.57%US$480.00US$400.00US$265.166
US$324
Fair Value
18.9% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/13 12:38
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.
Patrick DonnellyCitigroup Inc